Fig 1.
*15 Patients had both doses of apixaban on the index date, so they were not included in the analysis. AF: atrial fibrillation; BID: twice daily; ICD-10-CM: International Classification of Disease, 10th Revision, Clinical Modification; VTE: venous thromboembolism.
Table 1.
Baseline characteristics for PSM-adjusted 5 mg BID apixaban and warfarin and 2.5 mg BID apixaban and warfarin patients.
Table 2.
Number of events and incidence rates of clinical outcomes within 1 year for 5 mg BID apixaban and warfarin patients.
Fig 2.
Cumulative incidence and hazard ratios of stroke/systemic embolism among 5 mg BID apixaban/warfarin patients.
(A) Cumulative incidence of stroke/SE among propensity-score–matched 5 mg BID apixaban and warfarin patients. (B) Hazard ratios of stroke/SE for propensity-score–matched 5 mg BID apixaban and warfarin patients. BID, twice daily; stroke/SE, stroke/systemic embolism.
Table 3.
Number of events and incidence rates of clinical outcomes within 1 year for 2.5 mg BID apixaban and warfarin patients.
Fig 3.
Cumulative incidence and hazard ratios of stroke/systemic embolism among 2.5 mg BID apixaban/warfarin patients.
(A) Cumulative incidence of stroke/SE among propensity-score–matched 2.5 mg BID apixaban and warfarin patients. (B) Hazard ratios of stroke/SE for propensity-score–matched 2.5 mg BID apixaban and warfarin patients. Footnote: BID: twice daily; stroke/SE, stroke/systemic embolism.
Fig 4.
Cumulative incidence and hazard ratios of major bleeding among 5 mg BID apixaban and warfarin patients.
(A) Cumulative incidence of major bleeding among propensity-score–matched 5 mg BID apixaban and warfarin patients. (B) Hazard ratio of major bleeding for propensity-score–matched 5 mg BID apixaban and warfarin patients. BID, twice daily.
Fig 5.
Cumulative incidence and hazard ratios of major bleeding among 2.5 mg BID apixaban and warfarin patients.
(A) Cumulative incidence of major bleeding among propensity-score–matched 2.5 mg BID apixaban and warfarin patients. (B) Hazard ratio of major bleeding for propensity-score–matched 2.5 mg BID apixaban and warfarin patients. BID: twice daily; GI: gastrointestinal bleeding; ICH: intracranial hemorrhage.